This publication summarises the clinical benefits, safety and tolerability of faricimab (Vabysmo®), a bispecific antibody targeting vascular endothelial growth factor (VEGF)-A and angiopoietin (Ang)-2, for the treatment of neovascular age-related macular degeneration (nAMD). Faricimab is now funded in New Zealand for nAMD and diabetic macular oedema, for patients who meet Special Authority Criteria.
Please login below to download this issue (PDF)